EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban

Tan Ru San, Mark Yan Yee Chan, Teo Wee Siong, Tang Kok Foo, Ng Kheng Siang, Sze Huar Lee, Ching Chi Keong

Thrombosis · 2012

DOI: 10.1155/2012/108983 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis, 2012. Verfasst von Tan Ru San und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, National Heart Centre Singapore, 17 Third Hospital Avenue, Singapore 168752 ; Duke-NUS Graduate Medical School, 8 College R…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Bayer Healthcare.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Unlike vitamin K antagonists (VKAs), the new oral anticoagulants (NOACs)—direct thrombin inhibitor, dabigatran, and direct activated factor X inhibitors, rivaroxaban, and apixaban—do not require routine INR monitoring. Compared to VKAs, they possess relatively rapid onset of action and short halflives, but vary in relative degrees of renal excretion as well as interaction with p-glycoprotein membrane transporters and liver cytochrome P450 metabolic enzymes. Recent completed phase III trials comparing NOACs with VKAs for stroke prevention in atrial fibrillation (AF)—the RE-LY, ROCKET AF, and ARISTOTLE trials—demonstrated at least noninferior efficacy, largely driven by significant reductions in haemorrhagic stroke. Major and nonmajor clinically relevant bleeding rates were acceptable compared to VKAs. Of note, the NOACs caused significantly less intracranial haemorrhagic events compared to VKAs, the mechanisms of which are not completely clear. With convenient fixed-dose administration, the NOACs facilitate anticoagulant management in AF in the community, which has hitherto been grossly underutilised. Guidelines should evolve towards simplicity in anticipation of greater use of NOACs among primary care physicians. At the same time, the need for caution with their use in patients with severely impaired renal function should be emphasised.

Autor:innen und Institutionen

  • Department of Cardiology, National Heart Centre Singapore, 17 Third Hospital Avenue, Singapore 168752 ; Duke-NUS Graduate Medical School, 8 College Road, Singapore 169857.

Förderung

  • Bayer Healthcare

Zitieren

APA

Ru San, T., Chan, M. Y., Wee Siong, T., Kok Foo, T., Kheng Siang, N., Lee, S. H., & Chi Keong, C. (2012). Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban. Thrombosis. https://doi.org/10.1155/2012/108983

Vancouver

Ru San T, Chan MY, Wee Siong T, Kok Foo T, Kheng Siang N, Lee SH, et al. Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban. Thrombosis. 2012. doi:10.1155/2012/108983

BibTeX
@article{RuSan2012,
  author = {Ru San, Tan and Chan, Mark Yan Yee and Wee Siong, Teo and Kok Foo, Tang and Kheng Siang, Ng and Lee, Sze Huar and Chi Keong, Ching},
  title = {Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban},
  journal = {Thrombosis},
  year = {2012},
  doi = {10.1155/2012/108983}
}
Kostenlos starten →